Positive early results seen for CAR T-cell therapy for myeloma in trial
Most patients with hard-to-treat multiple myeloma given NXC-201 — Nexcella’s experimental point-of-care CAR T-cell therapy — as part of a clinical trial in…
News
FDA joins EU and Japan in deciding if Abecma may treat RRMM earlier
The U.S. Food and Drug Administration (FDA) has agreed to review an application that, if approved, would allow the cell therapy Abecma (idecabtagene…
Adding Aphexda helps to collect more stem cells for ASCT in trial
Aphexda (formerly motixafortide), BioLineRx’s experimental add-on therapy, greatly increased the number of blood stem cells collected for autologous stem cell transplants (ASCT), a life-extending…
CAR T-cell therapy, CB-011, on FDA fast track for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has given a fast track designation to CB-011, an experimental CAR T-cell therapy being developed by…
New mouse models may accelerate multiple myeloma research
More than a dozen new mouse models of multiple myeloma, which researchers hope will advance understanding and treating the disease, were described in a…
ISB 1442 antibody therapy wins US orphan drug status
ISB 1442, Ichnos Sciences’Â investigational bi-specific antibody-based treatment, has earned orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or…
EasyM, blood test for residual myeloma activity, certified in US
Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual…
Fatty acid-binding proteins may be potential target for myeloma
Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for multiple myeloma, a new…
Prominent voices to help spotlight myeloma risk in Black communities
Janssen and radio host and comedian D.L. Hughley are partnering to call attention to multiple myeloma in Black communities, with a goal of…
Goal of Myeloma Action Month? Telling the community’s stories.
For this Myeloma Action Month (MAM), observed each March to call attention to multiple myeloma and those affected by the blood disorder, the…
